phibro animal health - PAHC

PAHC

Close Chg Chg %
23.76 -0.02 -0.08%

Closed Market

23.74

-0.02 (0.08%)

Volume: 132.86K

Last Updated:

Nov 22, 2024, 4:00 PM EDT

Company Overview: phibro animal health - PAHC

PAHC Key Data

Open

$23.88

Day Range

23.71 - 24.34

52 Week Range

9.49 - 25.98

Market Cap

$962.37M

Shares Outstanding

40.50M

Public Float

19.97M

Beta

0.51

Rev. Per Employee

N/A

P/E Ratio

55.35

EPS

$0.43

Yield

202.02%

Dividend

$0.12

EX-DIVIDEND DATE

Nov 27, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

183.16K

 

PAHC Performance

1 Week
 
-2.94%
 
1 Month
 
1.32%
 
3 Months
 
13.37%
 
1 Year
 
125.24%
 
5 Years
 
0.55%
 

PAHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About phibro animal health - PAHC

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets medicated feed additives, nutritional specialty products, and vaccines. The Mineral Nutrition segment includes formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

PAHC At a Glance

Phibro Animal Health Corp.
Glenpointe Centre East
Teaneck, New Jersey 07666-6712
Phone 1-201-329-7300 Revenue 1.02B
Industry Pharmaceuticals: Major Net Income 2.42M
Sector Health Technology 2024 Sales Growth 4.069%
Fiscal Year-end 06 / 2025 Employees 1,940
View SEC Filings

PAHC Valuation

P/E Current 55.346
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 281.376
Price to Sales Ratio 0.668
Price to Book Ratio 2.647
Price to Cash Flow Ratio 7.758
Enterprise Value to EBITDA 11.059
Enterprise Value to Sales 1.071
Total Debt to Enterprise Value 0.482

PAHC Efficiency

Revenue/Employee 524,576.804
Income Per Employee 1,245.361
Receivables Turnover 6.006
Total Asset Turnover 1.042

PAHC Liquidity

Current Ratio 2.944
Quick Ratio 1.641
Cash Ratio 0.561

PAHC Profitability

Gross Margin 30.706
Operating Margin 6.133
Pretax Margin 1.073
Net Margin 0.237
Return on Assets 0.247
Return on Equity 0.896
Return on Total Capital 0.309
Return on Invested Capital 0.32

PAHC Capital Structure

Total Debt to Total Equity 204.745
Total Debt to Total Capital 67.186
Total Debt to Total Assets 53.499
Long-Term Debt to Equity 190.228
Long-Term Debt to Total Capital 62.422
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Phibro Animal Health - PAHC

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
833.35M 942.26M 977.89M 1.02B
Sales Growth
+4.12% +13.07% +3.78% +4.07%
Cost of Goods Sold (COGS) incl D&A
560.88M 655.42M 678.41M 705.19M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
31.89M 32.70M 34.01M 36.18M
Depreciation
23.16M 23.78M 24.32M 26.52M
Amortization of Intangibles
8.72M 8.92M 9.70M 9.66M
COGS Growth
+3.28% +16.86% +3.51% +3.95%
Gross Income
272.47M 286.84M 299.47M 312.49M
Gross Income Growth
+5.91% +5.27% +4.40% +4.35%
Gross Profit Margin
+32.70% +30.44% +30.62% +30.71%
2021 2022 2023 2024 5-year trend
SG&A Expense
196.51M 207.34M 219.50M 250.07M
Research & Development
17.76M 20.83M 24.39M 29.19M
Other SG&A
178.75M 186.51M 195.10M 220.88M
SGA Growth
+6.81% +5.51% +5.86% +13.93%
Other Operating Expense
- - - -
-
Unusual Expense
4.41M 4.62M (1.74M) (5.40M)
EBIT after Unusual Expense
71.55M 74.88M 81.72M 67.82M
Non Operating Income/Expense
5.32M 7.24M 900.00K (19.39M)
Non-Operating Interest Income
838.00K 816.00K 3.35M 4.47M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
10.40M 9.79M 28.55M 37.51M
Interest Expense Growth
-27.28% -5.91% +191.70% +31.41%
Gross Interest Expense
10.40M 9.79M 28.55M 37.51M
Interest Capitalized
- - - -
-
Pretax Income
66.47M 72.33M 54.07M 10.92M
Pretax Income Growth
+19.74% +8.81% -25.24% -79.81%
Pretax Margin
+7.98% +7.68% +5.53% +1.07%
Income Tax
12.08M 23.15M 21.46M 8.50M
Income Tax - Current - Domestic
986.00K 6.34M 11.61M 4.75M
Income Tax - Current - Foreign
13.28M 17.61M 12.75M 15.74M
Income Tax - Deferred - Domestic
181.00K 176.00K (6.42M) (6.28M)
Income Tax - Deferred - Foreign
(2.36M) (979.00K) 3.52M (5.72M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
54.38M 49.17M 32.61M 2.42M
Minority Interest Expense
- - - -
-
Net Income
54.38M 49.17M 32.61M 2.42M
Net Income Growth
+62.09% -9.58% -33.69% -92.59%
Net Margin Growth
+6.53% +5.22% +3.33% +0.24%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
54.38M 49.17M 32.61M 2.42M
Preferred Dividends
- - - -
-
Net Income Available to Common
54.38M 49.17M 32.61M 2.42M
EPS (Basic)
1.3437 1.2141 0.805 0.0596
EPS (Basic) Growth
+62.01% -9.65% -33.70% -92.60%
Basic Shares Outstanding
40.47M 40.50M 40.50M 40.50M
EPS (Diluted)
1.3427 1.2141 0.805 0.0596
EPS (Diluted) Growth
+62.08% -9.58% -33.70% -92.60%
Diluted Shares Outstanding
40.50M 40.50M 40.50M 40.52M
EBITDA
107.85M 112.21M 113.99M 98.60M
EBITDA Growth
+2.09% +4.04% +1.59% -13.50%
EBITDA Margin
+12.94% +11.91% +11.66% +9.69%

Snapshot

Average Recommendation UNDERWEIGHT Average Target Price 17.00
Number of Ratings 5 Current Quarters Estimate 0.425
FY Report Date 12 / 2024 Current Year's Estimate 1.542
Last Quarter’s Earnings 0.35 Median PE on CY Estimate N/A
Year Ago Earnings 1.19 Next Fiscal Year Estimate 1.866
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 5 5
Mean Estimate 0.43 0.43 1.54 1.87
High Estimates 0.48 0.51 1.85 2.04
Low Estimate 0.34 0.34 1.12 1.32
Coefficient of Variance 16.02 16.36 17.78 16.40

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 2 2 1
UNDERWEIGHT 1 1 1
SELL 2 2 2
MEAN Underweight Underweight Underweight

Insider Actions for Phibro Animal Health - PAHC

Date Name Shares Transaction Value
Feb 12, 2024 Glenn C. David Chief Financial Officer 300,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Phibro Animal Health in the News